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of psoriasis. Methods: A systematic literature search was conducted and studies 
were identified from PubMed and conference proceedings. Studies published in 
English language between January 2001 and May 2013, and reporting direct and 
indirect economic burden of psoriasis were identified using search strategies. A 
total of 1,181 abstracts were screened by two researchers; any discrepancy was 
resolved by a third researcher. Results: Forty studies (34 primary articles and 6 
conference abstracts) from 12 countries including 19 from the US, 4 from Canada, 3 
from Germany, 2 each from Italy, The Netherlands and the UK, 1 each from Australia, 
Brazil, Israel, Spain, Sweden and Switzerland, and 2 multinational studies met the 
inclusion criteria. Overall, 27 studies assessed direct costs, 3 studies assessed 
indirect costs, and 10 studies evaluated both. Major contributors of direct costs 
included medication costs, office visits, hospitalization costs and monitoring costs. 
Productivity loss, patient and caregiver work days lost, and restricted activity days 
were key drivers of indirect costs. Among the European countries, the most recent 
studies reported an annual total cost (direct and indirect cost) per patient of € 11,928 
in Sweden, € 8,372 in Italy, and € 2,866 - € 6,707 in Germany based on treatment type. 
In US and Canada, the annual direct and indirect economic burden of psoriasis was 
$1.4 billion and CDN$1.7 billion respectively. ConClusions: Costs associated with 
chronic plaque psoriasis are high in many countries indicating a continued need 
for new treatments.
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objeCtives: To identify the real world standard of care, treatment patterns, medi-
cal history, resource use and costs of patients with choroidal neovascularization 
(CNV) secondary to pathologic myopia (PM) in Canada. Methods: With enroll-
ment still ongoing, 85 patients with Myopic CNV were recruited by ophthalmolo-
gists and retina specialists from 16 centres across Canada to participate in this 
retrospective, multicenter study. Medical records covering at least one year of fol-
low up data from the CNV diagnosis, and up to two years, were analyzed to gather 
all information related to Myopic CNV. Results: Data from 67 study participants 
was analyzed. Patients had a mean age of 55.4 years (range: 27 – 80 years) at the 
time of their PM diagnosis (CNV affected eye), and 56.0 years (range: 29 - 82 years) 
at the time of their first lifetime CNV episode. The analysis showed that 71.6% 
of participants were female, 71.6% were Caucasian, 61.2% had subfoveal CNV in 
the affected eye and 31.3% had more than one lifetime CNV episode reported. 
Based on their visual acuity at the time of CNV diagnosis at the beginning of the 
chart review period, they were grouped by the Snellen score of the affected eye 
into 7 groups: 20/32-20/20 (n= 5), 20/50-20/32 (n= 5), 20/80-20/50 (n= 15), 20/125-
20/80 (n= 12), 20/200-20/125 (n= 2), 20/320-20/200 (n= 7) and < = 20/320 (n= 21). The 
approximate mean Snellen score was 20/160 in the affected eye and 20/63 in the 
fellow eye. The proportion of patients that had both eyes affected with PM was 
58.2%. ConClusions: Information on Myopic CNV is very limited in the literature. 
The baseline characteristics of Canadian patients presented here are aligned with 
other few data available in the public domain. This is the first study worldwide 
investigating the burden of Myopic CNV and the final results, will help us better 
understand this debilitating disease.
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objeCtives: Retinal vein occlusion (RVO) is the most common retinal vascular dis-
order with the potential for significant vision-related morbidity. The societal costs 
associated with CRVO are little known. Only a few studies reports on the burden of 
retinal vein occlusion or the resource use and cost of Central Retinal Vein Occlusion 
(CRVO). No specific burden of illness study is available that describes the situation in 
France. The purpose of the current study was to create a model that enables study of 
the societal costs of CRVO in France. The perspective of the model was prepared from 
a societal perspective. Methods: The input for health care utilisation input, were 
derived from a client survey conducted among French clinical experts in ophthal-
mology. An incidence-based model was constructed, which included the following 
parameters: direct and indirect costs, including treatment with drugs, non-drug 
treatments (e.g., grid laser photocoagulation and pan retinal photocoagulation), 
monitoring of the disease, adverse events, lost productivity, transportation and the 
cost of blindness. Results: In France the incidence of people suffering from CRVO 
was estimated to 10,471 (2011). The average annual contribution from each patient 
to the overall cost of CRVO was calculated to 11,434€ . The yearly direct and indirect 
costs were estimated to app. 120mill Euros. The contributing factors driving the 
cost of CRVO, in France, are, cost of blindness 29%, drug treatment cost 26%, cost of 
adverse events 25% and cost from monitoring 14%. ConClusions: Despite CRVO 
being a uncommon disease, the annual costs to the French society, based on the 
incidence of CRVO, are substantial. The cost of blindness account for 26% of the 
total annual costs indicating that there is a potential for reducing those costs with 
improved treatment options in CRVO.
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objeCtives: To describe the best supportive care costs of psoriasis patients follow-
ing discontinuation of conventional systemic or biologic therapy. Methods: Adult 
patients with ≥ 2 psoriasis diagnoses (from office visits) with continuous insurance 
5-dimension National Eye Institute Refractive Error Quality of Life (NEI-RQL)-42 
scale; expenditure on spectacles was also measured. Results: The proportion of 
patients with a postoperative improvement in visual acuity of 0.1 logMAR or better 
was significantly higher with the multifocal IOL than with monofocal lenses (45.7% 
vs. 2.1%, respectively; P< 0.0001), as was the proportion of patients achieving spec-
tacle independence (73.3% vs. 25.3%, P< 0.0001). At 6 months, the group difference 
in NEI-RQL-42 scores for dependence on correction significantly favoured the mul-
tifocal IOL (mean difference 37.3, 95% confidence interval 28.7–46.0, P< 0.0001), but 
there were no significant differences between the groups in scores for the other four 
dimensions (near vision, appearance, limitation in activity, and satisfaction with 
correction). The mean costs of spectacles in patients with multifocal or monofocal 
IOLs were € 154.42 and € 267.21, respectively, for lenses and € 66.59 and € 74.35, respec-
tively, for frames. ConClusions: Compared with monofocal IOLs, the multifocal 
IOL resulted in greater spectacle independence and lower expenditure on glasses. 
These findings are consistent with those of a previous economic modelling study, 
which showed that the use of this lens resulted in significant cost savings due to a 
reduced need for spectacles.
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objeCtives: The aim was to analyze the total direct costs of treatment of cutane-
ous drug reactions (CDR) from health care provider and public payer perspective 
divided by diagnosis groups. Methods: We analyzed retrospectively data from 
164 patients (57 men, 107 women) hospitalized in the Department of Dermatology, 
Military Medical Institute in Warsaw (from 2002 to 2012) due to CDR. Total direct 
costs from the public payer and health care provider were calculated for different 
diagnoses (based on ICD 10 codes). The analysis was based on data derived from 
the patients’ medical charts, daily medication logs, and cost data provided by the 
hospital organization and accounting department. The services paid by National 
Health Fund (NHF) were grouped based on ICD-10 and DRG system. For the pur-
pose of the analysis the hospitalization costs were calculated based on the prices 
for medical services established by the NHF on the basis of a contract with the 
selected health institution. Results: In the study group 3 CDR groups were iden-
tified: J38-severe skin disease (generalized rash) J39-large dermatological diseases 
(erythema multiforme) J49-gentle dermatological diseases (urticaria). From NHF 
perspective the most expensive procedure is J 38 – 962 € per patient (1€ = 4.24 PLN), 
the lower cost is for J39 and J 49 (476€ and 331€ respectively). From health care 
provider’s perspective the total direct costs equal: J38 – 630 € , J 39 – 552 € , J49 – 375€ . 
Differences in costs could be due to high costs of the clinically severe diseases treat-
ment incurred by the provider while according to the NHF, these units are classified 
as large dermatological diseases and thereby direct treatment costs are much lower 
than real provider’s costs. ConClusions: The analysis results suggest taking into 
consideration reclassification of the services by NHF or better estimation of DRG 
groups by the public payer.
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objeCtives: The societal costs associated with CRVO are little known. Only a few 
studies report on the burden of retinal vein occlusion, the resource use and cost of 
CRVO. No specific burden of illness study is available that describes the situation in 
the UK. The purpose of this study was to create a model that enabled the calcula-
tion of the societal costs of CRVO in the UK. Methods: The health care utilisation 
inputs for the model were derived from a survey conducted among UK ophthalmol-
ogy experts. The model included parameters that contribute to the costs of illness 
of CRVO and is based on the prevalence of CRVO in the UK. These were direct and 
indirect costs including drug treatment, non-drug treatment (e.g. grid laser photo-
coagulation and pan retinal photocoagulation), monitoring of the disease, adverse 
events, lost productivity, transportation and the cost of blindness. Results: In 
the UK, the average annual contribution from each patient to the overall cost of 
CRVO was calculated to £14,692. The annual cost for the UK society was estimated 
to be almost £700 million. The main part of the cost, 42%, was from monitoring of 
the disease. Also, 20% was from the cost of blindness, 16% from the drug treatment 
and 15% from treatment of adverse events. ConClusions: Despite CRVO being an 
uncommon disease, the annual costs to the UK society are substantial. The total 
burden of CRVO is most sensitive to changes in the cost associated with interven-
tions, with the number of hospital visits, ophthalmoscopy examinations and the 
number of optical coherence tomography (OCT) procedures as the dominating fac-
tors. By reducing the cost and/or the number of interventions by 25%, the overall 
burden of CRVO decreases from £14,692 to £13,147 per patient, which corresponds 
to a societal saving of almost £73 million per year.
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objeCtives: Psoriasis is a significant economic burden to both patients and pay-
ers in terms of direct and indirect costs. Previous systematic reviews have been 
limited with regards to geographical region of assessment and type of economic 
outcomes reported. Hence, the objective of this systematic review is to provide a 
global comprehensive understanding of the direct and indirect economic burden 
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treatment, shortening “patient paths” and establishing centers of wound treat-
ment would be recommended in Hungary.
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objeCtives: In Italy, standard treatment care of patients with neovascular (“wet”) 
age-related macular degeneration (wAMD) is currently performed with ranibi-
zumab (RBZ) on as-needed basis (PRN). The objective of this study was to assess 
the cost-effectiveness of intravitreal aflibercept (IVT-AFL), administered every 
other month vs. RBZ PRN treatment, in the Italian treatment setting. Methods: 
A Markov model was built to compare IVT-AFL compared to RBZ PRN in wAMD. 
Health states were based on visual acuity in the better-seeing eye. In the model, 
patients may remain in the same status (same visual acuity), progress to another 
status or die. A proportion of patients may also discontinue treatment monthly 
or upon becoming blind. Parameters were estimated from two randomized phase 
III studies VIEW 1/VIEW 2, published literature or expert opinions. Analyses were 
performed from the Italian Healthcare perspective, using a 20-year time hori-
zon (starting age was 77 years). The simulation model calculated costs (drug, 
administration, monitoring, vision impairment and adverse events), quality-
adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs), all 
discounted at 3% annually. Deterministic and probabilistic sensitivity analyses 
(SA) were performed to test the robustness of the results. Results: IVT-AFL 
costs 30,852€ compared with 33,636€ for RBZ PRN; QALYs totaled 2.651 for IVT-
AFL and 2.638 for RBZ-PRN respectively. IVT-AFL is associated with less cost and 
more QALYs gained than RBZ-PRN and hence dominates RBZ PRN. Deterministic 
SA showed that the results were most sensitive to changes in efficacy and time 
horizon, while probabilistic SA showed that 90% of the iterations fell within the 
cost-effectiveness threshold deemed acceptable for Italian Payers (for example 
€ 40,000). ConClusions: Results indicate that, within the Italian treatment set-
ting, attainment of maximal visual gains via IVT-AFL is cost-saving that means less 
costly and more effective (more QALYs gained) compared to RBZ PRN.
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objeCtives: To evaluate the cost-effectiveness of ranibizumab compared with 
verteporfin photodynamic therapy (vPDT) for the treatment of patients with visual 
impairment due to choroidal neovascularization (CNV) secondary to pathologic 
myopia (PM). Methods: A Markov model with a 3-month cycle length and health 
states defined by best-corrected visual acuity (BCVA) was developed from the UK 
health care provider perspective. A lifetime time horizon was applied, and future 
costs and outcomes were discounted at 3.5%/year. Baseline characteristics were 
derived from the phase 3 RADIANCE study; year 1 health state transitions and 
treatment frequency were based on the RADIANCE study and a vPDT study (VIP). 
Treatment was given beyond year 2 only in cases of mCNV recurrence (6%/year). 
Existing literature was used to estimate BCVA transitions beyond 12 months. Health 
states were based on the visual acuity of the study eye, which could be each patient’s 
better-seeing eye (BSE) or worse-seeing eye (WSE). BSE utility values came from a 
published source. Results: The mean lifetime cost of ranibizumab treatment was 
slightly lower than the cost of vPDT. Ranibizumab was associated with higher life-
time quality-adjusted life-years (QALYs) than vPDT (relative gain of 0.43), reflecting 
higher utility values and reduced mortality with ranibizumab. Ranibizumab there-
fore dominated vPDT. Ranibizumab had a 100% probability of being cost-effective 
compared with vPDT at a willingness-to-pay threshold of £20 000 per QALY. The 
model was sensitive to the number of ranibizumab injections in year 1. Ranibizumab 
remained cost-effective even when the mean number of ranibizumab injections 
increased from 3.5 (base case) to 12 and the mean number of vPDT treatments 
remained constant (3.4) in year 1. ConClusions: Ranibizumab is less costly and 
is associated with a gain in QALYs relative to vPDT for the treatment of patients 
with visual impairment due to CNV secondary to PM in the UK.
PSS23
CoSt-effeCtiveneSS of BiologiC theraPieS for the treatMent of 
Moderate to Severe PSoriaSiS in the united KingdoM
Betts K.A.1, Sundaram M.2, Mughal F.3, Yan S.Y.1, Signorovitch J.1, Wang K.2, Wu E.Q.1
1Analysis Group, Inc., Boston, MA, USA, 2AbbVie Inc., North Chicago, IL, USA, 3AbbVie Ltd., 
Maidenhead, Berkshire, UK
objeCtives: To evaluate the cost-effectiveness of biologic treatments for moderate 
to severe psoriasis in the UK. Methods: A decision model similar to those utilized 
in NICE appraisals TA103, TA134, TA146, and TA180 was constructed consisting of 
2 distinct periods, the trial and treatment periods. Clinical efficacy was estimated 
during the trial period based on the relative probabilities of achieving Psoriasis Area 
and Severity Index (PASI) response (50/75/90) obtained via a network meta-analysis 
of 15 randomized controlled trials of adalimumab, etanercept, infliximab, and usteki-
numab. Weight-based dosing was calculated for infliximab and ustekinumab to reflect 
licensed use. Only patients who achieved PASI 75 response in the trial period contin-
ued into the treatment period. Treatment benefits were determined by the relation-
ship between predicted PASI response and the EQ-5D health utility measure. Costs 
(2011 British pounds) were assessed from a UK National Health Services perspec-
tive and included drug acquisition, administration, monitoring and hospitalization 
coverage ≥ 6 months before (baseline period) and ≥ 12 months post-index date were 
selected from the MarketScan Commercial and Medicare Claims database (2005-2009). 
The index date was defined as the last day of conventional systemic or biologic drug 
coverage. Discontinuation was defined as no systemic or no biologic treatment for ≥ 
12 consecutive months from the last day of systemic or biologic prescription coverage. 
Patients were classified as having discontinued from a biologic if there was evidence 
of biologic drug use during the baseline period; otherwise they were defined as hav-
ing discontinued from non-biologic systemic therapy. Twelve-month average costs 
following discontinuation were reported. Results: A total of 4,720 psoriasis patients 
met the selection criteria; 67.4% discontinued from non-biologic systemic therapy 
and 32.6% from biologic therapy. Over the 12-month period following discontinu-
ation, total costs were $10,577 (SD: 19,910) and $9,001 (SD: 16,401) for biologic and 
non-biologic discontinuers, respectively (p= 0.004). Outpatient and medication costs 
were significantly higher for the biologic discontinuers compared to the non-biologic 
discontinuers ($5,283 vs. $4,449, p= 0.003, and $2,738 vs. $2,470, p= 0.022, respec-
tively). There was no statistically significant difference in hospital/ER costs ($2,556 
vs. $2,083, p= 0.214, respectively). Outpatient costs accounted for approximately 50% 
of total costs for both cohorts. ConClusions: This study suggests that outpatient 
costs account for a substantial proportion of health care costs in psoriasis patients 
who discontinued from systemic or biologic therapy. Patients who had discontinued 
from biologic therapy incurred significantly higher outpatient and medication costs 
compared to patients who had discontinued from conventional systemic therapy.
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objeCtives: Chronic leg ulcers without healing tendency present a serious public 
health and socio-economic issue. Rationally combinig causal and conservative treat-
ments with innovative methods, it would be beneficial to improve the effectivity of 
wound treatment, thus reducing its financial impacts. The aim of study was to inves-
tigate the cost of conservative treatment and an innovative Negative Pressure Wound 
Therapy (NPWT). Methods: The authors present cases of dermatological patients 
with severe, chronic leg ulcers of various etiologies resistant to conservative therapy 
(Patients-1: fasciitis necrotisans; Patients-2: ulcer associated with chronic venous 
insufficiency; Patients-3: pyoderma gangrenosum), thus comparing the costs of con-
servative treatment (social insurance subsidies on bandages) and NPWT (not financed 
by social insurance) in each patient. Furthermore, the authors compare costs of NPWT 
cases with other cases (Patient-4: fasciitis necrotisans; Patient-5: ulcer associated with 
chronic venous insufficiency; Patient-6: ulcer associated with rheumatoid arthritis), 
in which no NPWT was applied thus far due to financial reasons. (1USD$= 225 HUF, 
Hungarian Forint). Results: Social insurance subsidies on bandages/patient (USD) 
in treatment period: Patient-1.: $1324; Patient-2.: $15495; Patient-3.: $412; Patient-4.: 
$11376; Patient-5.: $10557; Patient-6.: $7306. Cost of NPWT/patient and proportion of 
social insurance subsidies on bandages/patient: Patient 1.: $1405 (106%); Patient 2.: 
$667 (4.3%), Patient 3.: $778 (188.9%). The cost of NPWT is relatively high, however, 
NWPT-treated leg ulcers have healed compared to cases receiving conservative treat-
ment, which can be attributed to NPWT stimulating wound healing. ConClusions: 
Treatment of the disease resulting leg ulcer – causal therapy combined with NPWT – is 
beneficial in wound healing, reducing high costs of wound treament, shortening the 
time of wound healing, improving the patient’s quality of life. Application of NPWT 
in specialized centers of wound treatment and financing by social insurance would 
be recommended for cases not responding to conservative treatment in Hungary.
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objeCtives: Incidence of chronic leg ulcers without healing tendency exceeds 1% 
among adults and 3-5% among people over 65 years. The burden of diseases caused 
by wounds without healing tendencies can only be estimated. Complications of 
chronic wounds are severe, life-threatening. Total social insurance subsidies on 
bandages in Hungary is 22-26 million USD/year. Using case studies the authors 
emphasize the importance of (differential) diagnosis, mistakes of wound treat-
ment affecting healing and increasing costs of treatment, in contrast to therapy 
costs. Methods: The authors present leg ulcer cases of various etiologies referred 
to the dermatological clinic, seeking mistakes of wound treatment, examining 
social insurance subsidies on bandages, based on bandage prescriptions. Patients 
1-4.: Ulcus cruris due to chronic venous insufficiency; Patient 5.: Leg ulcer caused 
by lymphoedema; Patients 6-8.: Ulcerous malignancies treated as leg ulcers; 
Patient 9.: Ulcus cruris+myeloproliferative disease; Patient 10.: Bilateral leg ulcers 
resulting from cardial decompensation and diabetes mellitus. (1USD$= 225 HUF, 
Hungarian Forint). Results: Social insurance subsidies (USD) on bandages per 
patients and mistakes in wound therapy: Patient 1.: $1857; Patient 2.: $1639; Patient 
3.: $1787; Patient 4.: $53329, lack of compression therapy and lymphatic massage; 
Patient 5.: $12.567, lack of lymphatic massage; Patient 6.: $213; Patient 7.: $294; 
Patient 8.: $2143, lack of correct diagnosis; Patient 9.: $2993, no treatment of con-
comitant hematologic disease; Patient 10.: insufficient therapy of co-morbidities: 
diabetes, obesity, cardial decompensation. ConClusions: Modern treatment of 
leg ulcers mainly aims at determining primary causes, treating diseases causing 
wound healing disorders, namely causal therapy. Inefficient wound treatment 
is costly, application of modern bandages without principles, not treating co-
morbidities and treating on inadequete levels cause financial problems to both the 
patient and the social insurance. Introducing professional guidelines for wound 
